Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.44 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | ITGAV | P06756 | 10/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.38 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710167 | 0.89 | APP (0.43) | CXCR4APPITGAVITGB3ITGB6 | |
| SCHEMBL12705298 | 0.89 | APP (0.48) | CXCR4APPITGAVITGB3ITGB6 | |
| SCHEMBL12705474 | 0.88 | ITGAV (0.35) | CXCR4ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL19752007 | 0.87 | APP (0.45) | CXCR4APPITGAVITGB3ITGB6 | |
| SCHEMBL12705294 | 0.85 | APP (0.60) | CXCR4APPITGAVITGB3ITGB6 | |
| SCHEMBL12705227 | 0.75 | APP (0.38) | APP | |
| SCHEMBL13355352 | 0.69 | CXCR4 (0.67) | CXCR4ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL13355366 | 0.69 | ITGB3 (0.62) | CXCR4ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL12705222 | 0.68 | F2 (0.42) | — | |
| SCHEMBL19752026 | 0.68 | F2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488513-B1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC IMMUNE SA (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| EP-2311823-A1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC Immune S.A. (CH) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | APP, CLN6, DPYSL2 | CXCR4 3189/4885APP 1/4885ITGAV 4373/4885 |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | APP, CLN6, DPYSL2 | CXCR4 3189/4885APP 1/4885ITGAV 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.